mGluR4 Positive Allosteric Modulators for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, anxiety disorders, and other conditions lack effective solutions for managing motor symptoms and neuroprotection, with existing therapies becoming less effective over time and associated with adverse effects, while there is a need for novel approaches that target metabotropic glutamate receptor 4 (mGluR4) for therapeutic benefits.
Innovation Solution
Development of compounds of formula I, which are positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGluR4), offering a broader opportunity for selective modulation and potential therapeutic benefits in treating Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, cancer, depression, and type 2 diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric agonists are used to target mGluR4, then receptor activation is achieved, but selectivity between mGluR subtypes is reduced due to similarity in ligand binding domains
Solution Approach 1:
The patent employs positive allosteric modulators as intermediary molecules that bind to a distinct allosteric site on mGluR4, rather than the orthosteric site. This intermediary binding approach allows selective modulation of mGluR4 activity without competing with endogenous ligands at the conserved orthosteric site, thereby achieving both reliable receptor activation and subtype selectivity.
Solution Approach 2:
The invention targets a specific local region (allosteric site) on the mGluR4 receptor that is distinct from the orthosteric binding domain. By focusing modulation activity on this localized region with unique structural characteristics, the compounds achieve selective interaction with mGluR4 while sparing other mGluR subtypes that lack this specific allosteric site configuration.
2Reliability
If existing Parkinson's disease treatments are used, then motor symptoms are managed initially, but effectiveness decreases over time and adverse effects emerge
Solution Approach 1:
Instead of using dopamine replacement or augmentation strategies that have become less effective over time, the patent inverts the approach by targeting the glutamatergic system through mGluR4 modulation. This alternative pathway activation provides a different mechanism for symptom control that does not suffer from the same tolerance development and adverse effect profile as conventional dopaminergic therapies.
3Ease of operation
If dopamine agonists and levodopa are used for Parkinson's disease, then motor symptoms are effectively treated early in the disease, but adverse effects including dyskinesias emerge
Solution Approach 1:
The patent converts the harmful overactivation of dopaminergic pathways (which causes dyskinesias) into a beneficial approach by modulating the glutamatergic system instead. By using positive allosteric modulators of mGluR4, the therapy achieves symptom relief through a different neurotransmitter system, thereby avoiding the harmful side effects associated with excessive dopaminergic stimulation while still addressing the underlying pathophysiology of Parkinson's disease.
Data Source
Figure 1
AI summary
The present invention relates to compounds of formula (I) wherein R1 is hydrogen, F or CI; L is a bond or lower alkylene; R2 is -(CH2)nO-lower alkyl, lower alkyl substituted by halogen, -(CH2)nC(0)0-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, =0, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by -(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or -(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof. The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.